About PCMA’s Policy Forum
Dismay over the price of prescription drugs continues to pervade politics and popular culture. Last year, the Inflation Reduction Act, with its Medicare Part D redesign and drug negotiation provisions, shifted the dynamics of the prescription drug market and policymakers continue to look for ways to address high drug costs. Proposed solutions include boosting competition by reducing paten abuses, increasing the number of biosimilars on the market, and exploring the role of pharmacy benefit companies (PBMs).
PCMA’s Policy Forum will feature policymakers – including key Administration officials and Congressional staffers – and PBM executives to discuss how the public and private sectors are tackling drug costs and improving both the affordability and quality of care for patients. Speakers will address topics highlighted in the PCMA Affordable Future policy platform, which focuses on increasing competition to bolster the private market, providing clinicians with data and tools to enhance patient care, and supporting and protecting patients.
Who Should Attend?
The PCMA Policy Forum is designed for policymakers and staff from Capitol Hill and federal agencies, as well as healthcare and drug industry advocates from think tanks, patient advocacy groups, industry trade associations, health industry companies and the media.
Attendees must register for this free event which has been organized to conform to House and Senate Ethics guidance for widely attended gatherings, with more than 25 individuals from outside organizations in attendance from throughout the industry.
Registered attendees must be affiliated with, and attending this event on behalf of a company or organization. Please be sure to indicate your affiliation when you register.
All members of the media must check in with PCMA at the registration desk upon arrival at the event.